Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Brammer Bio
Sort By
Newest First
1 / 2
1 / 2
Investment
Investing at the Intersection of Industrial Manufacturing and Healthcare
David Q. Anderson
Ampersand Capital Partners
PAP-Q2-20-CL-025
Jul 01, 2020
Viral Vector Manufacturing
Accelerating The Development of Viral Vector Manufacturing Processes
Richard Snyder, Ph.D.; Clive Glover, Ph.D.; Rajiv Vaidya, Ph.D.; Matt Niloff
Thermo Fisher Scientific
PAP-Q2-2019-CL-009
May 24, 2019
Executive Q&A
Q&A: Building a Successful CDMO Brand
Ampersand Capital Partners
PAP-Q2-2019-CL-024
May 24, 2019
M&A
Brammer Bio Purchased by Thermo Fisher Scientific
Nice Insight
PAO-M03-19-NI-032
Mar 28, 2019
Acquistion
Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing
Brammer Bio
PR-M03-19-NI-078-2821
Mar 25, 2019
QPCR
Digital Droplet PCR for Viral Vector Analysis
Richard Snyder, Ph.D.; Susan D'Costa, Ph.D.; Sushma Ogram, Ph.D.; Diego Matayoshi
Thermo Fisher Scientific
PAP-Q1-2019-CL-005
Mar 12, 2019
Facility
DPS Group Selected to Design Two cGMP Commercial Manufacturing Facilities for Brammer Bio
Brammer Bio
PR-M01-19-NI-036-3172
Jan 09, 2019
Appointment
Brammer Bolsters Leadership Team and Announces Chief Quality Officer
Brammer Bio
PR-M01-19-NI-019
Jan 04, 2019
Viral Vector Manufacturing
From Proof of Concept to Commercialization
Brammer Bio
PAP-Q4-18-CL-003
Oct 26, 2018
Cell and Gene Therapy
Analytical Methodologies Utilized in Therapeutic Viral Vector Manufacturing
Richard Snyder, Ph.D.; Sushma Ogram, Ph.D.; Tony DeFusco
Thermo Fisher Scientific
PAP-Q3-18-CL-001
Oct 02, 2018
Cell and Gene Therapy
Brammer Bio Announces Progress on $200 Million Program to Advance Gene Therapies
Brammer Bio
PR-M09-18-NI-096
Sep 26, 2018
Cell and Gene Therapy
Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing
Richard Snyder, Ph.D.; Christopher K. Murphy; Susan D'Costa, Ph.D.; Cameron Jones
Thermo Fisher Scientific
PAP-Q2-18-CL-011
May 29, 2018
Appointment
Brammer Bio Expands Leadership Team for Commercial Readiness
Brammer Bio
PR-M03-18-NI-080
Mar 22, 2018
Viral Vector
Ensuring Confidence in Viral Vector Manufacturing
Michael Wourms; Christopher K. Murphy
Arranta Bio
PAP-Q1-18-CL-012
Mar 12, 2018
Cell and Gene Therapy
Brammer Bio Supports Rare Disease Day 2018
Brammer Bio
PR-M03-18-NI-006
Mar 01, 2018
Cell and Gene Therapy
Brammer Bio Completes Renovations at Manufacturing Site in Massachusetts
Nice Insight
PAO-M12-17-NI-006-5009
Dec 05, 2017
Bioprocessing
Brammer Bio Leverages Advanced Bioprocessing Technologies to Accelerate Capacity
Nice Insight
PAO-M10-17-NI-002
Oct 03, 2017
Transient Transfection
Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing
Richard Snyder, Ph.D.; Scott Jeffers, Ph.D.; Ying Cai, Ph.D.
Thermo Fisher Scientific
PAP-Q3-17-CL-005
Sep 15, 2017
CDMO
Supporting the Tech Transfer Continuum for Cell & Gene Therapies
Richard Snyder, Ph.D.; Matthew Caple; Jessica Tate, Ph.D.
Thermo Fisher Scientific
PAP-Q2-17-CL-003
Jun 05, 2017
Investing for Successful Advancement of Viral Vector Manufacturing
Brammer Bio
PAP-Q1-17-CL-007
Mar 08, 2017
